These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1004 related articles for article (PubMed ID: 32698790)

  • 1. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
    Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
    BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Antoniotti C; Rossini D; Pietrantonio F; Catteau A; Salvatore L; Lonardi S; Boquet I; Tamberi S; Marmorino F; Moretto R; Ambrosini M; Tamburini E; Tortora G; Passardi A; Bergamo F; Kassambara A; Sbarrato T; Morano F; Ritorto G; Borelli B; Boccaccino A; Conca V; Giordano M; Ugolini C; Fieschi J; Papadopulos A; Massoué C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Fontanini G; Boni L; Galon J; Cremolini C;
    Lancet Oncol; 2022 Jul; 23(7):876-887. PubMed ID: 35636444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
    Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C
    BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
    Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
    Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
    Cremolini C; Loupakis F; Masi G; Lonardi S; Granetto C; Mancini ML; Chiara S; Moretto R; Rossini D; Vitello S; Allegrini G; Tonini G; Bergamo F; Tomasello G; Ronzoni M; Buonadonna A; Bustreo S; Barbara C; Boni L; Falcone A
    Ann Oncol; 2016 May; 27(5):843-9. PubMed ID: 26861604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
    Cremolini C; Antoniotti C; Lonardi S; Aprile G; Bergamo F; Masi G; Grande R; Tonini G; Mescoli C; Cardellino GG; Coltelli L; Salvatore L; Corsi DC; Lupi C; Gemma D; Ronzoni M; Dell'Aquila E; Marmorino F; Di Fabio F; Mancini ML; Marcucci L; Fontanini G; Zagonel V; Boni L; Falcone A
    JAMA Oncol; 2018 Apr; 4(4):529-536. PubMed ID: 29450468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer.
    Miyo M; Kato T; Yoshino T; Yamanaka T; Bando H; Satake H; Yamazaki K; Taniguchi H; Oki E; Kotaka M; Oba K; Miyata Y; Muro K; Komatsu Y; Baba H; Tsuji A
    BMC Cancer; 2020 Jul; 20(1):687. PubMed ID: 32703200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
    Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
    Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
    Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.
    Cremolini C; Marmorino F; Bergamo F; Aprile G; Salvatore L; Masi G; Dell'Aquila E; Antoniotti C; Murgioni S; Allegrini G; Borelli B; Gemma D; Casagrande M; Granetto C; Delfanti S; Di Donato S; Schirripa M; Sensi E; Tonini G; Lonardi S; Fontanini G; Boni L; Falcone A
    Eur J Cancer; 2019 Mar; 109():175-182. PubMed ID: 30735919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
    Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.
    Oki E; Kato T; Bando H; Yoshino T; Muro K; Taniguchi H; Kagawa Y; Yamazaki K; Yamaguchi T; Tsuji A; Iwamoto S; Nakayama G; Emi Y; Touyama T; Nakamura M; Kotaka M; Sakisaka H; Yamanaka T; Kanazawa A
    Clin Colorectal Cancer; 2018 Jun; 17(2):147-155. PubMed ID: 29530335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
    Antoniotti C; Boccaccino A; Seitz R; Giordano M; Catteau A; Rossini D; Pietrantonio F; Salvatore L; McGregor K; Bergamo F; Conca V; Leonetti S; Morano F; Papiani G; Tamburini E; Bensi M; Murgioni S; Ross DT; Passardi A; Boquet I; Nielsen TJ; Galon J; Varga MG; Schweitzer BL; Cremolini C
    Clin Cancer Res; 2023 Jun; 29(12):2291-2298. PubMed ID: 37022350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibitors in Mismatch Repair Proficient/Microsatellite Stable Metastatic Colorectal Cancer Patients: Insights from the AtezoTRIBE and MAYA Trials.
    Germani MM; Moretto R
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
    Cremolini C; Marmorino F; Loupakis F; Masi G; Antoniotti C; Salvatore L; Schirripa M; Boni L; Zagonel V; Lonardi S; Aprile G; Tamburini E; Ricci V; Ronzoni M; Pietrantonio F; Valsuani C; Tomasello G; Passardi A; Allegrini G; Di Donato S; Santini D; Falcone A;
    BMC Cancer; 2017 Jun; 17(1):408. PubMed ID: 28599628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
    JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer.
    Satake H; Ando K; Oki E; Shimokawa M; Makiyama A; Saeki H; Tsuji A; Mori M
    BMC Cancer; 2020 Nov; 20(1):1116. PubMed ID: 33203393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
    Stein A; Atanackovic D; Hildebrandt B; Stübs P; Brugger W; Hapke G; Steffens CC; Illerhaus G; Bluemner E; Stöhlmacher J; Bokemeyer C
    Br J Cancer; 2015 Sep; 113(6):872-7. PubMed ID: 26335608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.